Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Non-Current Assets (2016 - 2025)

Theravance Biopharma has reported Other Non-Current Assets over the past 13 years, most recently at $836000.0 for Q4 2025.

  • Quarterly Other Non-Current Assets changed 0.0% to $836000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $836000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $836000.0 for FY2025, 0.0% changed from the prior year.
  • Other Non-Current Assets was $836000.0 for Q4 2025 at Theravance Biopharma, down from $25.2 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $25.2 million in Q3 2025 and troughed at $833000.0 in Q1 2021.
  • The 5-year median for Other Non-Current Assets is $836000.0 (2022), against an average of $3.4 million.
  • The largest YoY upside for Other Non-Current Assets was 2913.28% in 2025 against a maximum downside of 89.41% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $837000.0 in 2021, then soared by 724.25% to $6.9 million in 2022, then tumbled by 87.88% to $836000.0 in 2023, then changed by 0.0% to $836000.0 in 2024, then changed by 0.0% to $836000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Other Non-Current Assets are $836000.0 (Q4 2025), $25.2 million (Q3 2025), and $836000.0 (Q2 2025).